A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PAC / prostatic adenocarcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 51
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PAC  (>> Co-occurring Abbreviation)
Long Form:   prostatic adenocarcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. DAC, NPV, PPV
2022 RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures. EMT, TCC
2022 Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC). ---
2021 Ablation of Red Stable Transfected Claudin Expressing Canine Prostate Adenocarcinoma and Transitional Cell Carcinoma Cell Lines by C-CPE Gold-Nanoparticle-Mediated Laser Intervention. C-CPE, CLDN, GNOME-LP, SEM, TCC
2021 Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma. AR, DDR, DHT, mCRPC, PSA
2021 Aptamer Probes Labeled with Lanthanide-Doped Carbon Nanodots Permit Dual-Modal Fluorescence and Mass Cytometric Imaging. FFPE, IFM, IMC, ROI
2021 Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. AR, BRCA2, CDK12, IDC-P, NCOR2, PCa, TP53
2021 Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma. DA, HGPIN, IHC, NPH
2021 HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma. HOXB13, IHC, PC, PSA, pTNM, TFF3
10  2021 Optimizing the diagnosis and management of ductal prostate cancer. DAC
11  2020 Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis. TCC
12  2020 Delayed 68Ga-PSMA PET/CT Image-Guided Biopsy for Low-Grade Adenocarcinoma in Benign Prostatic Hyperplasia. ---
13  2020 Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. ADT, DAC, MFS, OS, RP
14  2020 Metal-Labeled Aptamers as Novel Nanoprobes for Imaging Mass Cytometry Analysis. 167Er-DTPA, IMC, MAP
15  2020 Metastatic prostate adenocarcinoma to cervical lymph nodes: an unusual diagnosis on fine-needle aspiration biopsy. FNAB
16  2020 [Clinical features and epidemiological trend of prostate cancer in the Changsha area of Hunan Province: Analysis of 2 877 cases]. ---
17  2016 Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma. AMACR, GATA3, PAP, PSA, PSMA, UC
18  2016 GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. ADT, CREB, NED, NEPC
19  2016 Prostate cancer: from Gleason scoring to prognostic grade grouping. ---
20  2016 Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? CHOP, LHRH, MCL, MSCT, PSA
21  2015 A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. AR, NED, NEPC, PCa
22  2015 Structural study of endopelvic fascia in prostates of different weights. Anatomic study applied to radical prostatectomy. ---
23  2014 Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients. MAC, NPH, TCC
24  2013 A novel subtype of primary prostatic adenocarcinoma: A case report. PSA, UC
25  2013 Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. DAC, PCDF
26  2011 IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. HGPIN, IGFBP2
27  2009 The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. CAD, CgA, NE, PC, PSA
28  2009 Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors. UC
29  2008 Primary prostatic central zone adenocarcinoma. CZ, HGPIN
30  2007 Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. IT
31  2007 Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. PSMA, UBC
32  2007 Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases. CEA, CK20, CK7, FNAB, PAP, PSA
33  2007 The 3-dimensional structure of isolated and small foci of prostatic adenocarcinoma: the morphologic relationship between prostatic adenocarcinoma and prostatic intraepithelial neoplasia. HGPIN, ISPAC
34  2004 The effectiveness of artificial neural networks in evaluating treatment plans for patients requiring external beam radiotherapy. DVH
35  2003 A simple technique for calculation of the volume of prostatic adenocarcinomas in radical prostatectomy specimens. BPH, GS, PZ, RP, TZ
36  2003 Col IV and Fn distribution in prostatic adenocarcinoma and correlation of 67LR, MMP-9 and TIMP-1 expression with Gleason score. BM, BPH, Col IV, FN, MMP-9, TIMP-1
37  2002 High-dose rate brachytherapy of prostatic adenocarcinoma in combination with external beam radiotherapy a long-term follow-up of the first 50 patients at one center. ---
38  2002 Identification of isolated and early prostatic adenocarcinoma in radical prostatectomy specimens with correlation to biopsy cores: clinical and pathogenetic significance. ISPAC, NTZ, TZ
39  2002 Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. CK, PAP, PSA, TM, UC, UP
40  2001 Primary and secondary prostatic adenocarcinoma of the urinary bladder. ---
41  2001 Transitional zone and anterior peripheral zone of the prostate. A correlation of small-volume cancer in the biopsy cores and high psa with positive anterior margins in radical prostatectomy specimens. APZ, PPZ, RP, TZ
42  2000 Correlations among prostatic biopsy results, transrectal ultrasound findings and PSA levels in diagnosing prostate adenocarcinoma. PSA, TRUS
43  2000 Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. PSA, RR, RT-PCR
44  1999 Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. BPH
45  1998 [A case of poorly differentiated adenocarcinoma of prostate with neuroendocrine differentiation]. NE
46  1997 Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network. BBN, NP, PIN
47  1996 Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. bp, CD44s
48  1996 Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. NP, PIN
49  1996 [Significance of argyrophil staining for nucleolar organizer regions (AgNORs) to pathologic diagnosis of prostatic adenocarcinoma]. AgNORs, PH, TSC
50  1995 Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. BM
51  1994 Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. ABs, CET, NP, PCNA, PIN